Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020)136
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-1991
Antimicrobial peptides (AMPs): a patent review (2015–2020)50
Repurposing drugs for the management of COVID-1946
Natural compounds and extracts as novel antimicrobial agents45
Antibiotic resistance and bacterial biofilm44
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)42
Biofilm and Quorum Sensing inhibitors: the road so far39
An updated patent review of VEGFR-2 inhibitors (2017-present)37
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents36
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)36
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)35
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)33
Synthetic molecules as DprE1 inhibitors: A patent review32
The therapeutic potential of PROTACs32
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present32
An updated patent review of anticancer Hsp90 inhibitors (2013-present)31
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)29
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature29
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)28
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021)27
TRPV4 antagonists: a patent review (2015–2020)27
Factor XII(a) inhibitors: a review of the patent literature26
Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-202225
Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 – 202025
Soluble guanylate cyclase stimulators and their potential use: a patent review25
Thioredoxin reductase inhibitors: updated patent review (2017-present)25
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)24
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)24
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents23
Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates23
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)23
A patent review of transient receptor potential vanilloid type 1 modulators (2014–present)22
Protease inhibitors targeting the main protease and papain-like protease of coronaviruses22
Ligands for cereblon: 2017–2021 patent overview22
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective21
Steroid sulfatase inhibitors: the current landscape21
A patent review of topoisomerase I inhibitors (2016–present)21
Anti-viral activity of thiazole derivatives: an updated patent review20
A patent review of berberine and its derivatives with various pharmacological activities (2016–2020)20
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present)20
Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature20
Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)20
Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)20
Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 202119
Aurora kinase inhibitors: a patent review (2014-2020)18
An updated patent review of autotaxin inhibitors (2017–present)18
Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)18
Therapeutic approaches targeting the neurotensin receptors18
A patent review of MALT1 inhibitors (2013-present)18
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature18
JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)18
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)18
Recent updates on Wnt signaling modulators: a patent review (2014-2020)17
Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015–2020)17
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade17
Phosphoglycerate dehydrogenase (PHGDH) inhibitors: a comprehensive review 2015–202017
N-heterocyclic carbene metal complexes as therapeutic agents: a patent review17
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)16
Potential of microRNA based diagnostics and therapeutics in glioma: a patent review16
Patent landscape of pediatric-friendly oral dosage forms and administration devices16
Purposing plant-derived exosomes-like nanovesicles for drug delivery: patents and literature review16
An updated patent review on drugs for the treatment of tuberculosis (2018-present)16
Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)15
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)15
A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)15
Mucormycosis medications: a patent review15
0.019129037857056